Treating high-risk, HER2-negative breast cancer patients before surgery with the immunotherapy Imfinzi (durvalumab) plus Lynparza (olaparib) and chemotherapy increases the probability for complete cancer eradication, according to the results from a Phase 2 trial. The results showed the triple combination increased the likelihood of cancer eradication from the breast and lymph nodes when compared with chemotherapy alone. Lajos Pusztai, MD, DPhil, professor of medical oncology at Yale University, in Connecticut, presented the results in “Evaluation of durvalumab…
You must be logged in to read/download the full post.
The post Pre-Surgical Imfinzi Combo Increases Cancer Eradication Chances in Trial appeared first on BioNewsFeeds.